NOVATO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) ("Ultragenyx" or the "Company"), a biopharmaceutical company focused on the development of...
NOVATO, Calif. and CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) (“Ultragenyx” or the “Company”), a biopharmaceutical company focused on...
WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders PR Newswire NEW YORK, Oct. 13, 2017 NEW YORK, Oct. 13, 2017 /PRNewswire/ -- WeissLaw...
Harwood Feffer LLP Announces Investigation of Dimension Therapeutics, Inc. PR Newswire NEW YORK, Oct. 5, 2017 NEW YORK, Oct. 5, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is...
Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price? PR Newswire SAN DIEGO, Oct. 3, 2017 SAN DIEGO, Oct. 3...
Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares...
NOVATO, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) (“Ultragenyx” or the “Company”), a biopharmaceutical company focused on the development of...
ROCKVILLE, Md., Oct. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX) today announced that Dimension Therapeutics, Inc. (Nasdaq:DMTX) notified REGENXBIO that it has determined that...
CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX), a leader in discovering and developing new therapeutic products for people living with...
CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX) (“Dimension”), a leader in discovering and developing new therapeutic products for people...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約